Average Insider

Where insiders trade, we follow

$SGMT
Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional lipid metabolism pathways. Its lead drug candidate is Denifanstat, a FASN inhibitor for the treatment of nonalcoholic steatohepatitis and acne. The company is also developing TVB-3567, a FASN inhibitor for the treatment of various types of cancers. The company was formerly known as 3-V Biosciences, Inc. and changed its name to Sagimet Biosciences Inc. in August 2019. Sagimet Biosciences Inc. was incorporated in 2006 and is headquartered in San Mateo, California.
Healthcare
Sector
Biotechnology
Industry
David A. Happel
CEO
14
Employees
$7.05
Current Price
$159.66M
Market Cap
52W Low$4.50
Current$7.0536.9% above low, 63.1% below high
52W High$11.41

Insider Activity Statistics

Aggregated buying and selling activity by time period
PeriodTypeInsidersTransactionsValueSharesBuy/Sell Ratio
1 weekBuys00---
Sells00--
2 weeksBuys00---
Sells00--
1 monthBuys00--All Sells
Sells33$719,429.2893,440
2 monthsBuys00--All Sells
Sells33$719,429.2893,440
3 monthsBuys00--All Sells
Sells33$719,429.2893,440
See activity going back 12 months โ€” create a free account

Insider Transactions

Recent purchases and sales by company insiders
DateInsiderTypeSharesPriceValueActions
Jul 20, 2026
Happel David
Director
Sale64,051$7.76$497,067.79View Details
Jul 20, 2026
Rozek Elizabeth
Chief Legal&Admin. Officer
Sale10,545$7.76$81,832.36View Details
Jul 20, 2026
Kemble George
Director
Sale18,844$7.46$140,529.13View Details
5 more transactions available โ€” create a free account to see 12 months of history

Upcoming Earnings

Scheduled earnings reports
No upcoming earnings scheduled

Past Earnings

Historical earnings results
No earnings data in the last 3 months. Sign up free to see 12 months of history.
Version: v26.7.3